Non-valvular atrial fibrillation (NVAF) is a common heart rhythm disorder characterized by irregular and often rapid heartbeats. Unlike valvular atrial fibrillation, which is associated with heart valve issues, NVAF occurs in the absence of significant valve abnormalities. NVAF poses an increased risk of blood clots forming in the atria, which can potentially lead to stroke. Managing NVAF typically involves anticoagulant medications to prevent blood clot formation and control heart rate. Additionally, healthcare providers may explore rhythm control strategies to restore a normal heart rhythm. As NVAF is often a chronic condition, a comprehensive approach that considers individual patient factors is crucial for effective treatment and reducing the risk of associated complications. Regular monitoring and collaboration between patients and healthcare professionals are key components of managing non-valvular atrial fibrillation.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation